Five questions every sponsor should ask their CRO before a sarcoma programme begins 

At one major tertiary sarcoma centre, 26.6% of diagnoses submitted by referring pathologists were revised on specialist second opinion.¹ In soft tissue sarcoma more broadly, published error rates on first pathology review range from 14% to 47%.² 

In a clinical trial, a misclassified patient can compromise stratification, confound efficacy data and, in a disease with a tiny eligible population, waste months of recruitment. Resolving a substantial protocol amendment takes an average of roughly 260 days for global multi-site studies.³ In a rare subtype, where the eligible population may number in the low hundreds, it can decide whether the trial recruits at all. 

July is Sarcoma Awareness Month. Most of the conversation will rightly focus on patients and diagnosis. This article asks a different question: whether the operational system behind your sarcoma programme is built to match what the disease actually demands.

Two pressure points that decide whether your trial finishes recruiting

Each one is measurable, and each one is askable before a contract is signed.

Why sarcoma breaks the standard playbook

Sarcoma accounts for roughly 1% of adult cancers yet spans more than 50 distinct histological subtypes.² That combination, extreme rarity with extreme heterogeneity, creates operational challenges that standard oncology infrastructure is not designed for: site selection when the global eligible population for a subtype may number in the low hundreds, central pathology and imaging logistics across multiple countries with different tissue-shipment regulations, consent processes that must account for mid-study histological reclassification, and studies enrolling three to five patients per site across 15 or more countries.

Rare cancer development carries constraints that standard oncology trials do not: patient populations too small for conventional randomised designs, limited natural history data to design against, and often no adequate active comparator.⁴ The FDA’s Oncology Center of Excellence runs a dedicated Rare Cancers Program specifically in response to these constraints.⁵

France’s NETSARC network offers a measurable example of what structured adaptability looks like. Since 2010, it has mandated central pathology review and multidisciplinary tumour board discussion for every suspected sarcoma case across 26 reference centres.⁶ Across more than 43,000 patients, compliance with clinical practice guidelines rose steadily and outcomes improved with it.⁶ The lesson is not specific to pathology: adaptability that works at scale has to be designed into a workflow deliberately. It does not appear after a delay has already occurred.

In sarcoma and other rare tumour types, the highest-value intervention happens before the first patient is screened. TFS involves key opinion leaders early in protocol design to ensure the study reflects current clinical practice, eligibility criteria are realistic for the subtype, and endpoints hold up across enrolling sites. Once running, protocol deviations are reviewed monthly to catch emerging patterns before they escalate into amendments. The result is a design that supports enrolment and retention because it makes sense in the clinic from day one.

Five questions to ask your CRO before signing

The evidence points to five concrete, evaluable questions a sponsor can put to any CRO before a sarcoma programme begins. They are not about therapeutic expertise. They are about how the organisation around your study actually works.